Please assess the completion status of the following clinical trial:

Trial Title: Attenuation of the Side Effect Profile of Regadenoson: Study With Aminophylline in Patients With Severe Kidney Disease Undergoing Myocardial Perfusion Imaging

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adult patients referred to undergo a clinically-indicated regadenoson-stress myocardial perfusion imaging at Rush University Medical Center~* Stage IV or V chronic kidney disease (GFR \< 30, hemodialysis, and/or peritoneal dialysis).~Exclusion Criteria:~* Patient refusal to participate~* Known allergic reaction to aminophylline.~* Pre-existing headache or acute/subacute GI illness with symptoms of diarrhea, abdominal discomfort, nausea or vomiting.~* Any contraindication to aminophylline: hypotension, unstable cardiac arrhythmias and acute coronary symptoms.~* Uncontrolled seizure disorder defined as more than 2 seizure episodes in the past 12 months or any seizure in the past week.~* Pregnant or breast-feeding women.~* Patients receiving anti-platelet agent dipyridamole (Persantine® or Aggrenox®).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Aminophylline (Type: EXPERIMENTAL): 75 mg of intravenous aminophylline.
- Placebo (Type: PLACEBO_COMPARATOR): Matching 0.9 Normal Saline (sterile salt water)administered intravenously.

Based on this trial design, predict the completion outcome and termination type (if applicable).